Morgan Stanley lowered the firm’s price target on Procept BioRobotics (PRCT) to $68 from $71 and keeps an Overweight rating on the shares.The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation
- Buy Recommendation for Procept BioRobotics Supported by Favorable CMS Updates and Reimbursement Stability
- Procept BioRobotics says Aquablation therapy assigned a Category I code
- Procept BioRobotics initiated with an Overweight at Stephens
- Procept BioRobotics initiated with a Perform at Oppenheimer